When will the markets stall?

Published 20-OCT-2017 09:30 A.M.


3 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.

Click Here to View Latest Articles

“Soon” according to some analysts

Overnight, Citibank said that they see the potential for a 25 percent fall in global equities. They based their view on the global unwinding of monetary stimulus, which has helped to fuel the current rally in global equities.

As you can see by the below chart, as the US monetary authorities accumulated financial assets (primarily treasury securities), it helped to push share markets higher. Similar asset buying programs were also enacted (and are continuing) in Europe and Japan.

S&P 500 market

The past performance of this product is not and should not be taken as an indication of future performance. Caution should be exercised in assessing past performance. This product, like all other financial products, is subject to market forces and unpredictable events that may adversely affect future performance.

Now the US Federal Reserve has started to unwind its balance sheet, and the concern of Citi strategist Matt King (and indeed, many others) is that this could lead to a huge correction on global stock markets, in a manner similar to the impressive rally that we have witnessed.

In addition, Japan has started to reduce its own bond purchases and the Europeans are expected to follow suit. Mr King believes that “these policies are additive”, and that the results of an unwind “will be much greater than central banks imagine”.

Such a sell-down of Central Bank assets could take years to wash through to equity markets, a may need some sort of a catalyst to trigger share price depreciation.

Indeed, the traditionally bearish Society General also believe a pullback is likely, although they come at it from a different perspective. Soc Gen has been looking at US equity volatility data, and according to analyst Praveen Singh, US equities are “now entering dangerous volatility regimes.”

Soc Gen found that the current low level of volatility is incredibly rare, and that on the occasions that volatility has reached these levels, it has gone on to rise by 3 points over the following twelve months.

Apparently Soc Gen’s view is share by a host of hedge funds and investment managers, because according to Bloomberg “Brevan Howard Asset Management, 36 South Capital Advisors, One River Asset Management and at least three other firms are rolling out new funds designed to protect investors from rising market turbulence.” I.E they are rolling out long volatility funds.

This is also a view on share market falls, as volatility is usually inversely correlated with price movement; if volatility were to meaningfully increase, it would mean that share prices are broadly falling.

The view is also share by our most recent Nobel laureate in economics, Richard Thaler, who stated a few days ago that “We seem to be living in the riskiest moment of our lives, and yet the stock market seems to be napping.”

It is impossible to argue that US (and global) equity valuations are cheap by historical standards. In fact, by most measures, US stock valuations are heavily stretched; and will eventually pull back. Keep your eyes to the markets, because I feel it is not too far off.

This article is General Information and contains only some information about some elements of one or more financial products. It may contain; (1) broker projections and price targets that are only estimates and may not be met, (2) historical data in terms of earnings performance and/or share trading patterns that should not be used as the basis for an investment as they may or may not be replicated. Those considering engaging with any financial product mentioned in this article should always seek independent financial advice from a licensed financial advisor before making any financial decisions.

General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.


Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free